Atara Biotherapeutics Management
Management criteria checks 3/4
Atara Biotherapeutics' CEO is Pascal Touchon, appointed in Jun 2019, has a tenure of 5.25 years. total yearly compensation is $4.38M, comprised of 16.5% salary and 83.5% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth €248.65K. The average tenure of the management team and the board of directors is 3.7 years and 5.3 years respectively.
Key information
Pascal Touchon
Chief executive officer
US$4.4m
Total compensation
| CEO salary percentage | 16.5% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$181m |
| Mar 31 2024 | n/a | n/a | -US$233m |
| Dec 31 2023 | US$4m | US$723k | -US$276m |
| Sep 30 2023 | n/a | n/a | -US$290m |
| Jun 30 2023 | n/a | n/a | -US$305m |
| Mar 31 2023 | n/a | n/a | -US$215m |
| Dec 31 2022 | US$5m | US$718k | -US$228m |
| Sep 30 2022 | n/a | n/a | -US$247m |
| Jun 30 2022 | n/a | n/a | -US$248m |
| Mar 31 2022 | n/a | n/a | -US$350m |
| Dec 31 2021 | US$5m | US$681k | -US$340m |
| Sep 30 2021 | n/a | n/a | -US$328m |
| Jun 30 2021 | n/a | n/a | -US$318m |
| Mar 31 2021 | n/a | n/a | -US$311m |
| Dec 31 2020 | US$5m | US$655k | -US$307m |
| Sep 30 2020 | n/a | n/a | -US$304m |
| Jun 30 2020 | n/a | n/a | -US$301m |
| Mar 31 2020 | n/a | n/a | -US$298m |
| Dec 31 2019 | US$7m | US$319k | -US$291m |
Compensation vs Market: Pascal's total compensation ($USD4.38M) is above average for companies of similar size in the German market ($USD508.51K).
Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.
CEO
Pascal Touchon (61 yo)
5.3yrs
Tenure
US$4,375,125
Compensation
Dr. Pascal Touchon, D.V.M., serves as Independent Director at Ipsen S.A. since October 4, 2023. He has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 201...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$4.38m | 0.58% € 248.7k | |
| Executive VP and Chief Scientific & Technical Officer | 3.3yrs | US$2.28m | 0.25% € 108.8k | |
| Executive VP & Chief Legal Officer | 4.4yrs | US$2.31m | 0.22% € 95.3k | |
| Executive VP & Chief Financial Officer | 1.4yrs | no data | 0.18% € 79.2k | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Executive VP and Global Head of Regulatory Affairs & Quality | 4yrs | no data | 0.16% € 67.3k | |
| Executive VP & Chief Business Officer | 3.7yrs | no data | no data | |
| Senior VP & Chief Medical Officer | less than a year | no data | no data |
3.7yrs
Average Tenure
51yo
Average Age
Experienced Management: AT20's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$4.38m | 0.58% € 248.7k | |
| Independent Director | 8.8yrs | US$237.23k | 0.12% € 53.3k | |
| Independent Director | 10.5yrs | US$239.73k | 0.042% € 18.3k | |
| Lead Independent Director | 11.7yrs | US$260.23k | 0.34% € 148.3k | |
| Independent Director | no data | no data | no data | |
| Independent Director | 3.1yrs | US$219.52k | 0.017% € 7.2k | |
| Independent Director | 4.3yrs | US$229.73k | 0.026% € 11.1k |
5.3yrs
Average Tenure
60yo
Average Age
Experienced Board: AT20's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/14 17:43 |
| End of Day Share Price | 2024/06/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atara Biotherapeutics, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Yigal Nochomovitz | Citigroup Inc |
| Jonathan Miller | Evercore ISI |